New Delhi: AstraZeneca could potentially get the trial results of its coronavirus vaccine with Oxford University and file for its emergency use in the United States in late-January, health officials said on Wednesday. The British-Swedish drugmaker has already published interim efficacy results from their UK trial in November, but the results showed irregularities to scientists. Also Read - Coronavirus: Delhi Records 96 New Cases, Logs Below 100 For First Time in 9 Months
Notably, the development comes amid the UK government’s announcement to begin the vaccination drive against COID-19 infection as it became the West’s first country to formally endorse a jab at it. Also Read - Eating These Food Items Can Reduce Your Risk of Dying Owing to COVID-19
“I still expect that somewhere in January maybe, more towards the second half of January, data will become available and potentially an emergency use authorization could be filed,” said OWS chief adviser Moncef Slaoui. Also Read - Jayalalitha's Close Aide Sasikala Freed After Spending 4 Years in Jail, to Remain in Hospital For Now
While overall effectiveness of the Oxford vaccine stood at 70 per cent, AstraZeneca said the vaccine could be 90 per cent effective when given as a half dose followed by a full dose, based on a relatively small number of volunteers.
AstraZeneca had briefly paused its study in the vaccine trials in th US in October after a report of a serious neurological illness in a participant in the UK.
Meanwhile, in India, the Serum Institute of India (SII) will seek emergency use authorisation for the Oxford vaccine in about two weeks, said Adar Poonawalla, Founder and CEO, SII.